News
Olaparib demonstrated activity in a phase 2 trial of patients who had advanced biliary tract cancer with homologous recombination repair (HRR) mutations. Results from this trial were presented at the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results